Braidwell LP Acquires 31,809 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Braidwell LP increased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 18.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 200,500 shares of the company's stock after acquiring an additional 31,809 shares during the quarter. Braidwell LP owned about 0.70% of Krystal Biotech worth $31,410,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech in the third quarter worth $40,000. Covestor Ltd lifted its position in Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock worth $111,000 after buying an additional 642 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Krystal Biotech in the fourth quarter valued at about $119,000. KBC Group NV boosted its position in Krystal Biotech by 46.3% during the fourth quarter. KBC Group NV now owns 939 shares of the company's stock valued at $147,000 after purchasing an additional 297 shares during the last quarter. Finally, Blue Trust Inc. increased its position in shares of Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock worth $159,000 after purchasing an additional 433 shares during the last quarter. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Stock Down 3.6 %

Shares of KRYS traded down $4.94 during midday trading on Friday, reaching $132.23. 329,798 shares of the stock were exchanged, compared to its average volume of 299,978. The stock's 50 day simple moving average is $172.42 and its 200 day simple moving average is $170.36. The company has a market cap of $3.82 billion, a P/E ratio of 44.22 and a beta of 0.79. Krystal Biotech, Inc. has a twelve month low of $131.76 and a twelve month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). The company had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. As a group, analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 750 shares of the firm's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This trade represents a 1.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

KRYS has been the subject of several analyst reports. Citigroup raised their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. Chardan Capital reaffirmed a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Wednesday. HC Wainwright reiterated a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a report on Tuesday. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday, February 20th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $218.63.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).